Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.
about
Patient-derived tumour xenografts as models for oncology drug developmentPatient-derived tumor xenografts: transforming clinical samples into mouse modelsRebuilding cancer metastasis in the mouseCurrent status and evolution of preclinical drug development models of epithelial ovarian cancerDevelopment and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinomaMetformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived XenograftsUsing heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancerThe future of patient-derived tumor xenografts in cancer treatment.Ex vivo tumor culture systems for functional drug testing and therapy response predictionEstablishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasisGuidelines for the welfare and use of animals in cancer research.Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.In-vivo fusion of human cancer and hamster stromal cells permanently transduces and transcribes human DNA.The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer ModelsGeneration of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient miceEstablishment of genetically diverse patient-derived xenografts of colorectal cancer.Pre-clinical mouse models of human prostate cancer and their utility in drug discoveryPrediction of individual response to anticancer therapy: historical and future perspectivesEstablishing a human renal cell carcinoma tumorgraft platform for preclinical drug testingNew concepts in breast cancer genomics and geneticsTumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenograftsDecreasing the adverse effects of cancer therapy: an NCI Workshop on the preclinical development of radiation injury mitigators/protectors.Normal tissue protection for improving radiotherapy: Where are the Gaps?Genomic profiling of patient-derived colon cancer xenograft modelsPreclinical models of pancreatic ductal adenocarcinoma.Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer.HER2 as a novel therapeutic target for cervical cancer.Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer.Origin of the vasculature supporting growth of primary patient tumor xenografts.Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sitesHistologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma.Xenograft models of head and neck cancers.Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation.Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement.Human tumor xenografts and mouse models of human tumors: re-discovering the models.Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment.Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.Modeling of Patient-Derived Xenografts in Colorectal Cancer.
P2860
Q24604068-6908BA57-AD96-4D96-950C-AED63F442A93Q24627425-CE231ED9-62B2-40E6-8B53-1CD6F4A40731Q26864450-DE24AB11-CD4F-4E4B-B932-FA3AE44D10F6Q27028117-C1394A41-5C7B-4072-9427-0EF2E1F7D537Q28534618-B752774D-95F1-4138-8686-BB31FCB254C1Q28552408-F64249D1-39F6-4629-885E-1C46D11F75F2Q30409503-60728BCB-C375-410C-A80F-16DF6CA9C8E3Q33361578-F9E4BD5F-FB06-4A0D-B1A7-784602B62883Q33827247-474B637E-9743-49CA-9C0D-BEF36AA8890DQ33827461-8365C1CF-14A4-4463-B516-C07D7F1B486CQ33903753-21E3A505-B4A9-4A0C-8017-71CA7F864E10Q34122822-964F8282-E97A-4E6A-A144-FBA5047728E5Q34258171-C44A62FB-C5CC-4294-BF5E-7881C4253257Q34309954-E87C05D5-4289-4AB0-81AD-07E5C7E91FAFQ34372342-F2F58DF6-800C-48B2-8B30-ADBD1CF52BC1Q34704942-5BAE99AD-B1CC-44FB-ACA7-6C2F9C2A65A4Q34771567-60A4E7E6-6BA2-4231-B41A-3B60AF5CD386Q35024682-B9167679-84F2-4BD1-B356-7CB22F636AB4Q35041892-F95F9701-240D-462B-B425-2A87A876CF77Q35258057-61DEAA62-38EC-450C-A679-76412DF52905Q35534811-103271CF-10F9-4BEB-8626-FB5A37759EB2Q35638497-53B41798-92B3-47D0-AE7A-7E9A16C2BA1CQ35839058-260FCD06-E348-4DF9-B28D-41F8B6DA161CQ35878951-C6BEE0B0-2E06-4144-B431-05CE7523835EQ36137870-FCE655E3-4F21-4F03-9987-9578FDF3BB2EQ36153954-A2AE796A-FD91-4BC0-8956-AB471FA9F9ACQ36428208-83E6E834-D5BA-4C33-8033-E2F6F8D3B39FQ36521908-E6AF0EE9-CA31-433E-A51C-2B7D0338EBF6Q36546614-7320634D-8580-41D1-98D7-F6CBFF103247Q36633405-E1D8F7D1-3015-4793-9ADA-58D96622D1FFQ36863454-E6FA86E8-8B53-4B06-8B26-AD649DB7C9E3Q37086209-B8062F9F-1FC7-434B-9588-2030182D7697Q37272622-36DB88D4-3581-4EAB-AA16-5A03FDA1821DQ37332682-6B923703-7273-4482-ABF0-962BAD437972Q37542817-7F737EDB-73F2-4B65-935C-79CA67971EA7Q38045441-ED9B60C4-669E-4392-B9D3-1391C0C843F1Q38088348-7F7DB856-DC03-4714-9532-CBED40EAC198Q38233004-12257B83-C7FA-4578-B62D-547B185F0252Q38351470-4BB635F9-8EBA-40B8-952B-AAD111870412Q38705019-1BBE451C-D60A-4CA1-A20A-E6C7E6202EDC
P2860
Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Direct in vivo xenograft tumor ...... g response in cancer patients.
@en
Direct in vivo xenograft tumor ...... g response in cancer patients.
@nl
type
label
Direct in vivo xenograft tumor ...... g response in cancer patients.
@en
Direct in vivo xenograft tumor ...... g response in cancer patients.
@nl
prefLabel
Direct in vivo xenograft tumor ...... g response in cancer patients.
@en
Direct in vivo xenograft tumor ...... g response in cancer patients.
@nl
P2860
P921
P356
P1476
Direct in vivo xenograft tumor ...... g response in cancer patients.
@en
P2093
B Rubio-Viqueira
P2860
P2888
P304
P356
10.1038/CLPT.2008.200
P407
P577
2008-11-12T00:00:00Z
P6179
1021014583